US7599161095 - Common Stock - After market: 173.87 0 (0%)
NASDAQ:RGEN (12/8/2022, 3:30:01 PM)+3.54 (+2.08%)
|GICS Sector||Health Care|
|GICS Industry||Life Sciences Tools & Services|
|Earnings (Last)||11-01 2022-11-01/bmo||Earnings (Next)||02-15 2023-02-15|
|Ins Owners||0.65%||Inst Owners||91.55%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,852 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
Building 1, Suite 100, 41 Seyon Street
Waltham MASSACHUSETTS 02453
CEO: Tony J. Hunt
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers...
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement...
Here you can normally see the latest stock twits on RGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.